A Multicenter, Randomized, Parallel Group, Double Blind, Active and Placebo Controlled Study of BAY1753011, a Dual V1a/V2 Vasopressin Receptor Antagonist, in Patients With Congestive Heart Failure: AVANTI Study
Latest Information Update: 25 Jul 2022
At a glance
- Drugs Pecavaptan (Primary) ; Furosemide; Loop diuretics
- Indications Decompensated heart failure; Heart failure
- Focus Pharmacodynamics; Proof of concept
- Acronyms AVANTI
- Sponsors Bayer
Most Recent Events
- 14 Jun 2021 Status changed from active, no longer recruiting to completed.
- 08 Jun 2021 This trial has been completed in Greece, according to European Clinical Trials Database record.
- 04 Jun 2021 This trial has been completed in Bulgaria, according to European Clinical Trials Database record.